AIMZ Investment Advisors LLC Has $4.23 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

AIMZ Investment Advisors LLC reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,539 shares of the medical research company’s stock after selling 153 shares during the quarter. Amgen makes up approximately 1.5% of AIMZ Investment Advisors LLC’s holdings, making the stock its 19th biggest position. AIMZ Investment Advisors LLC’s holdings in Amgen were worth $4,230,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in AMGN. D Orazio & Associates Inc. lifted its position in Amgen by 1.1% during the 2nd quarter. D Orazio & Associates Inc. now owns 3,101 shares of the medical research company’s stock worth $969,000 after buying an additional 33 shares in the last quarter. Main Street Financial Solutions LLC increased its position in shares of Amgen by 10.2% in the second quarter. Main Street Financial Solutions LLC now owns 3,710 shares of the medical research company’s stock valued at $1,159,000 after acquiring an additional 342 shares during the last quarter. Lansing Street Advisors raised its holdings in Amgen by 1.8% during the second quarter. Lansing Street Advisors now owns 2,550 shares of the medical research company’s stock worth $797,000 after acquiring an additional 45 shares in the last quarter. Private Wealth Partners LLC boosted its position in Amgen by 30.0% during the second quarter. Private Wealth Partners LLC now owns 1,299 shares of the medical research company’s stock valued at $406,000 after purchasing an additional 300 shares during the last quarter. Finally, Hazlett Burt & Watson Inc. grew its stake in Amgen by 1.6% in the second quarter. Hazlett Burt & Watson Inc. now owns 3,253 shares of the medical research company’s stock valued at $1,015,000 after purchasing an additional 50 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.3 %

Shares of Amgen stock opened at $329.98 on Thursday. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The stock has a market cap of $177.01 billion, a PE ratio of 47.14, a PEG ratio of 2.85 and a beta of 0.61. The firm has a 50-day moving average of $327.34 and a 200-day moving average of $303.13. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same period in the prior year, the firm earned $5.00 EPS. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. As a group, sell-side analysts forecast that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.73%. Amgen’s dividend payout ratio is presently 128.57%.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of analyst reports. Oppenheimer reiterated an “outperform” rating and set a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price target (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Argus lifted their price objective on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Royal Bank of Canada upped their target price on shares of Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. Finally, Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.